|
ABS-103R:
THE NEXT GENERATION
VALPROATE
ABS-103R is a potent single isomer analogue of a
commonly prescribed anti-convulsant agent known as
valproate. Valproate is a frontline treatment for
epilepsy and is also indicated for migraine prophylaxis
(prevention) and treatment of mania associated with
bipolar depression. Sales of valproate are approximately
$1 billion worldwide. Despite its widespread use valproate
has serious side effects, which include teratogenicity
(birth defects and neurological damage), sedation
and fatal hepatotoxicity (liver damage). ABS, in collaboration
with researchers in its Global Scientific Network®,
has managed to isolate the characteristics of valproate
that account for its efficacy and those characteristics
that cause serious side effects. ABS-103R has been
shown to be free of the serious side effects associated
with valproate particularly birth defects and sedation.
ABS-103R is intended for the treatment and prevention
of epilepsy, migraine headache and mania associated
with bipolar depression.
Evaluation
of ABS-103R: A Comparison with Valproate
| Drug |
Anti-convulsant
Action (%)
|
Sedation
(%)
|
Embryo
Lethality (%)
|
Embryo
Neural Defects (%)
|
|
Valproate
|
100
|
33
|
49
|
42
|
| ABS-103R |
100
|
0
|
9
|
0
|
| Control |
—
|
0
|
9
|
0
|
•
ABS-103R demonstrates an improved safety profile compared
with Valproate.
ABS-103R
Demonstrates a Longer Duration of Action Compared
to Valproate
•
ABS-103 demonstrates a significantly longer duration
of action in the cortical ramp model of epilepsy compared
to valproate. A longer duration of action is important
as it represents a sustained therapeutic effect, which
can result in less frequent drug administration.
|
